The Motley Fool··Prosper Junior BakinyExelixis Charts Path to Doubling as Pipeline Star Poised to Offset Patent Cliff
Exelixis positions for potential doubling by 2031 as zanzalintinib pipeline candidate targets $5B peak sales, offsetting 2030 Cabometyx patent cliff.
EXELbiotechclinical trials